Hofseth BioCare ASA
Hofseth BioCare ASA
05/06/2022 | Press release | Distributed by Public on 05/06/2022 00:03
Hofseth Biocare ASA: FIRST QUARTER 2022 FINANCIAL REPORT
Tid06.05.2022, 06:00:03
MeldingsID561363
UtstederIDHBC
MarkedOslo Børs
Andre språk
Korrigerte versjoner
KategoriANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON
-
Informasjonspliktige opplysningerInformasjonspliktige opplysninger i henhold til lov, forskrift eller børsens egne regler for markedet verdipapiret er notert på.
-
Lagringspliktig meldingMed lagringspliktige meldinger menes meldinger som skal oppbevares i offisiell lagringsmekanisme (OAM) etter verdipapirhandelloven § 5-12 og/eller børsens egne regler.
Vedlegg
Del melding
Hofseth Biocare ASA: FIRST QUARTER 2022 FINANCIAL REPORT
HBC had gross operating revenues of NOK 30.8m (16.8m) in the first quarter
2022. Cost of sales (CoGS) amounted to NOK 22.1m (8.4m) in the quarter.
Operating profit (EBITDA) was NOK -26.2m (-18.8m) and Operating loss (EBIT)
amounted to NOK 33.5m (25.0m). Adjusting for one-off bulk sales of ProGo
inventory and R&D costs associated with the build-up of the CTU but not to be
recognized as intangible assets, gives an adjusted EBITDA of NOK -18.2m in the
first quarter.
Cash and cash equivalents decreased by NOK 19.3m during the quarter, leaving
total holding of cash and cash equivalents at NOK 30.6m by the end of the
period, compared to NOK 138.5m by the end of the first quarter 2021. Including
credit facilities, HBC had NOK 67.6m in free liquidity by the end of the first
quarter 2022.
Commercial update
The first quarter started will with a growth in sales in the ingredient business
of 93.5 % vs the previous period last year. The quarter ended with a sales of
NOK 31m compared to NOK 17m in Q1 of 2021. This is in line with the strong order
book of NOK 40m which was created in Q4 as indicated in the previous quarterly
report and during Q1.
The increase is coming from a significant improvement of sales prices throughout
all ingredients and a shift into higher value application like super premium pet
food, human nutrition, and nutritional supplements. This conversion from feed
and basic pet food is expected to continue in the remaining quarters of 2022 and
will contribute not only to the top line, but also to the bottom line.
Highlights in the first quarter
* The first quarter started with a growth in sales in the ingredient business
of 93.5 %, compared to the same period last year and record order book.
* Our first preclinical assay work of SPH peptides in prostate cancer was
published in the journal Marine Drugs this quarter. This work demonstrated
that, in combination with androgen deprivation therapy, the SPH peptides
enhance anti-tumour activity.
* Our first clinical trial for CalGo®, demonstrating the enhanced
absorbability of CalGo® compared to calcium carbonate in post-menopausal
women has been accepted for publication in the Biomedical Journal of
Scientific and Technical Research.
* We have identified 8 structurally similar peptides which drive the FTH1
actions of SPH. These peptides have previously unknown structures with novel
composition of matter claim potential. This will lead to a broader IP claim
set for HBC.
Please find the HBC Q1 2022 Financial report attached.
For further information, please contact:
Jon Olav Ødegård, Chief Financial Officer of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: [email protected]
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund,
Norway with branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act
2022. Cost of sales (CoGS) amounted to NOK 22.1m (8.4m) in the quarter.
Operating profit (EBITDA) was NOK -26.2m (-18.8m) and Operating loss (EBIT)
amounted to NOK 33.5m (25.0m). Adjusting for one-off bulk sales of ProGo
inventory and R&D costs associated with the build-up of the CTU but not to be
recognized as intangible assets, gives an adjusted EBITDA of NOK -18.2m in the
first quarter.
Cash and cash equivalents decreased by NOK 19.3m during the quarter, leaving
total holding of cash and cash equivalents at NOK 30.6m by the end of the
period, compared to NOK 138.5m by the end of the first quarter 2021. Including
credit facilities, HBC had NOK 67.6m in free liquidity by the end of the first
quarter 2022.
Commercial update
The first quarter started will with a growth in sales in the ingredient business
of 93.5 % vs the previous period last year. The quarter ended with a sales of
NOK 31m compared to NOK 17m in Q1 of 2021. This is in line with the strong order
book of NOK 40m which was created in Q4 as indicated in the previous quarterly
report and during Q1.
The increase is coming from a significant improvement of sales prices throughout
all ingredients and a shift into higher value application like super premium pet
food, human nutrition, and nutritional supplements. This conversion from feed
and basic pet food is expected to continue in the remaining quarters of 2022 and
will contribute not only to the top line, but also to the bottom line.
Highlights in the first quarter
* The first quarter started with a growth in sales in the ingredient business
of 93.5 %, compared to the same period last year and record order book.
* Our first preclinical assay work of SPH peptides in prostate cancer was
published in the journal Marine Drugs this quarter. This work demonstrated
that, in combination with androgen deprivation therapy, the SPH peptides
enhance anti-tumour activity.
* Our first clinical trial for CalGo®, demonstrating the enhanced
absorbability of CalGo® compared to calcium carbonate in post-menopausal
women has been accepted for publication in the Biomedical Journal of
Scientific and Technical Research.
* We have identified 8 structurally similar peptides which drive the FTH1
actions of SPH. These peptides have previously unknown structures with novel
composition of matter claim potential. This will lead to a broader IP claim
set for HBC.
Please find the HBC Q1 2022 Financial report attached.
For further information, please contact:
Jon Olav Ødegård, Chief Financial Officer of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: [email protected]
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new pharmaceutical drug leads. Research is ongoing to identify the
individual elements within its ingredients that modulate inflammation and the
immune response with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates are focused
on developing an oral treatment for inflammatory disease driven by eosinophils
(a type of white blood cell). Clinical trial work with the oil is ongoing to
ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of the lipids, proteins and calcium
from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund,
Norway with branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act